Incyte Corp.

NASDAQ:INCY   3:09:00 PM EDT
82.83
-0.40 (-0.48%)
Regulatory, Earnings Announcements

Incyte Announces First Data From Reach3 Trial Showing Ruxolitinib Significantly Improved Outcomes

Published: 12/04/2020 17:37 GMT
Incyte Corp. (INCY) - Incyte Announces First Data From Reach3 Trial Showing Ruxolitinib (jakafi®) Significantly Improved Outcomes in Patients With Steroid-refractory Or Steroid-dependent Chronic Graft-versus-host Disease.
Incyte Corp - Results of Reach3 Trial Also Demonstrate Significant Improvements in Failure-free Survival (ffs) and Patient-reported Symptoms.
Incyte Corp - Patients Treated With Jakafi Also Had Greater Improvements in Patient-reported Symptoms Than Those Treated With Bat.
Incyte Corp - Patients Receiving Jakafi Had a Significant Improvement in Failure-free Survival.
Incyte Corp - Best Overall Response Was Achieved in 76.4% of Patients in Jakafi Arm Compared to 60.4% in Bat Arm.
Revenue is expected to be $691.69 Million
Adjusted EPS is expected to be $0.58

Next Quarter Revenue Guidance is expected to be $735.63 Million
Next Quarter EPS Guidance is expected to be $0.60

More details on our Analysts Page.